Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.46 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.42 |
| ▸ | FEN1 | P39748 | 2/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.42 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20753255 | 0.90 | GPR119 (0.43) | GPR119EGLN2ALOX5APFEN1CHEK2 | |
| SCHEMBL30034262 | 0.87 | KDM1A (0.47) | GPR119EGLN2ALOX5APFEN1CETP | |
| SCHEMBL17559077 | 0.87 | KDM1A (0.43) | — | |
| SCHEMBL24659688 | 0.86 | KDM1A (0.56) | GPR119EGLN2KAT8KAT6AKAT5 | |
| SCHEMBL16808849 | 0.86 | KDM1A (0.56) | GPR119EGLN2KAT8KAT6AKAT5 | |
| SCHEMBL16797291 | 0.82 | KDM1A (0.58) | GPR119EGLN2CETP | |
| SCHEMBL17432965 | 0.81 | ALOX5AP (0.46) | GPR119EGLN2KAT8ALOX5APFEN1 | |
| SCHEMBL17427340 | 0.81 | KDM1A (0.49) | GPR119EGLN2KAT8ALOX5APFEN1 | |
| SCHEMBL16797266 | 0.81 | KDM1A (0.55) | GPR119EGLN2CHEK2CCNT1CDK9 | |
| SCHEMBL17427358 | 0.80 | KDM1A (0.52) | GPR119EGLN2ALOX5APFEN1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4257591-A2 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3080100-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-3080100-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-3189038-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2022-11-23 | — | — | EP | disclosed |
| CN-112125901-A | Inhibitors of lysine-specific demethylase-1 | 赛尔基因昆蒂赛尔研究公司 | 2020-12-25 | — | — | CN | disclosed |
| US-10864202-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| CN-107074787-B | Inhibitors of lysine-specific demethylase-1 | 赛尔基因昆蒂赛尔研究公司 | 2020-10-27 | — | — | CN | disclosed |
| US-10543198-B2 | Inhibitor of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20180179204-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180179204-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180028508-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180028508-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-02-01 | — | — | US | disclosed |
| US-9822119-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822119-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160304516-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. | 2016-10-20 | — | — | US | disclosed |
| US-20160304516-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. | 2016-10-20 | — | — | US | disclosed |
| US-20160108046-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160108046-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| WO-2016037005-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-10 | — | — | WO | disclosed |
| WO-2015089192-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179204-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | GPR119 2640/4885EGLN2 252/4885KAT8 210/4885 |
| US-10864202-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | GPR119 2640/4885EGLN2 252/4885KAT8 210/4885 |
| US-20180028508-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | GPR119 2640/4885EGLN2 252/4885KAT8 210/4885 |
| US-20160108046-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | GPR119 2640/4885EGLN2 252/4885KAT8 210/4885 |
| US-20160304516-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | GPR119 2640/4885EGLN2 252/4885KAT8 210/4885 |
| US-10543198-B2 | Inhibitor of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | GPR119 2618/4885EGLN2 248/4885KAT8 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.